Epirubicin/Vinorelbine Adjuvant Chemotherapy in Young Women with Breast Cancer is Associated with Preservation of Menstrual Function

Clinical Oncology

Volumn 20, Issue 7, 2008, Pages 513-516

  Zekri, J M ^a   El Helw, L M ^a   Purohit, O P ^a   Hatton, M Q ^a   Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Adjuvant chemotherapy; breast cancer; epirubicin; fertility; vinorelbine

Indexed keywords

DOCETAXEL; EPIRUBICIN; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE;

ADJUVANT THERAPY; ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEMALE FERTILITY; FOLLOW UP; HUMAN; LIVER METASTASIS; MEDICAL RECORD REVIEW; MENSTRUATION DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; PROBABILITY; SURVIVAL RATE; THROMBOPHLEBITIS;

ADULT; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FERTILITY; HUMANS; MEDICAL RECORDS; MIDDLE AGED; RETROSPECTIVE STUDIES; VINBLASTINE;

EID: 48349098138     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.03.016     Document Type: Article

References (17)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 56 2 (2006) 106-130
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 19 352 (1998) 930-942
3. Di Cosimo S., Alimonti A., Ferretti G., et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 15 (2004) 1065-1071
4. Bines J., Oleske D.M., and Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14 5 (1996) 1718-1729
5. Chua S., Smith I.E., A'hern R.P., et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial. Ann Oncol 16 9 (2005) 1435-1441
6. Ejlertsen B., Mouridsen H.T., Langkjer S.T., Andersen J., Sjostrom J., and Kjaer M. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 22 12 (2004) 2313-2320
7. Hortobagyi G.N., Buzdar A.U., Marcus C.E., and Smith T.L. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1 (1986) 105-109
8. Levine M.N., Bramwell V.H., Pritchard K.I., et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16 (1998) 2651-2658
9. Parulekar W.R., Day A.G., Ottaway J.A., et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5. J Clin Oncol 23 25 (2005) 6002-6008
10. Martin M., Pienkowski T., and Mackey J. Adjuvant docetaxel for node-positive breast cancer. New Engl J Med 352 22 (2005) 2302-2313
11. Goldhirsch A., Castiglione M., and Gelber R.D. Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases. Lancet 5 335 (1990) 1099-1100
12. Brusamolino E., Lunghi F., Orlandi E., et al. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity. Haematologica 85 10 (2000) 1032-1039
13. Fumoleau P., Delgado F.M., Delozier T., et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11 7 (1993) 1245-1252
14. Twelves C.J., Dobbs N.A., Curnow A., et al. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 70 5 (1994) 990-993
15. Vici P., Colucci G., Gebbia V., et al. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol 20 11 (2002) 2689-2694
16. Partridge A.H., Gelber S., Peppercorn J., et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22 20 (2004) 4174-4183
17. Poole CJ, Earl HM, Dunn JA, et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Annual ASCO meeting 2003 [Abstract 13].